What Phebra does

Phebra is an Australian-owned pharmaceutical manufacturer founded in 1993 (originally as Pharmalab, renamed Phebra in 2007) that develops, manufactures, and supplies sterile injectable critical care medicines for hospitals and healthcare professionals. Its portfolio spans more than 60 medicines across therapeutic areas including antidotes (Acetadote, DigiFab), cardiovascular drugs (Rapiblyk, Brevibloc, Narcan), oncology products (Phenasen/Arsenic Trioxide), pain management (Caldolor, Laceraine, Morphine Oral Solution), emergency and obstetric medicines, and diagnostic agents. Manufacturing is conducted at a TGA-licensed, GMP-compliant, FDA-accredited multi-purpose sterile injectables plant at Lane Cove West, Sydney, equipped with a robotic aseptic syringe and vial line; the facility was expanded in 2019 ($4M, +3,000m²) and again in 2020, with further capacity investment committed through 2026. Manufacturing licenses have been progressively broadened, in 2022 to include clinical trials therapeutic goods and in 2025 to include prescription oral and dermatological solutions.

The business operates through three revenue streams: direct product sales via the PhebWeb online ordering system and Therapeutic Specialist Representatives in Australia; licensing and distribution agreements with international partners (e.g., Flexipharm Austrading for the UK, Healthcare Logistics for NZ); and contract development and manufacturing services for other pharmaceutical companies. Customer segments are hospitals and healthcare professionals (primary), plus pharmaceutical companies seeking Asia-Pacific commercialization partners. Pricing is tiered across healthcare providers, licensed wholesalers, and credit accounts requiring minimum $10,000/quarter spend over three consecutive quarters. The group has established wholly-owned subsidiaries in the UK (2018), Canada (2019), New Zealand, and Singapore, holds a minority equity stake in Flexipharm Austrading (2021), and in 2024 launched subsidiary Phero Pharma to address Australian medicine shortages through in-licensing and alternative global sourcing.

Phebra's strategic posture is anchored in regulatory moats (TGA, FDA, GMP), a niche critical-medicines portfolio where supply security matters to hospitals, and incremental geographic and dosage-form expansion. Recent moves include pipeline expansion (Rapiblyk in March 2026, Anaesthetic Wound Gel in April 2026, Sterile Theatre Packs in 2023), a co-development partnership with the University of Wollongong for leukemia and pancreatic cancer drug development (2023), and a licensing deal with Medsenic for oral arsenic trioxide (2021). The company remains privately held with no disclosed funding rounds or revenue figures, and headcount is described as 'more than 130 people' against a stated 51-100 band.

Name

Phebra

Legal name

Phebra Pty Ltd

Website

https://phebra.com

Company type

Private

Founded year

1993

Operating status

Operating

Headcount range

51–100 employees

Short description

Phebra is an Australian pharmaceutical manufacturer founded in 1993 that develops, manufactures, and supplies sterile injectable critical care medicines to hospitals and healthcare professionals, operating TGA-licensed and FDA-accredited facilities in Sydney with subsidiaries across the UK, Canada, New Zealand, and Singapore.

Ownership category

akta.pro rank

Product category

Specialty Sterile Injectable Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO)

akta.pro secondary industries

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Respiratory & Allergy Pharmaceuticals (HLAIAAAH)

Keywords

• Sterile injectable pharmaceuticals
• Critical care medicines
• Pharmaceutical contract manufacturing
• Specialty hospital pharmaceuticals
• Clinical trial drug manufacturing

Headquarters

HQ city

Lane Cove

HQ country

Australia

HQ region

Oceania

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Direct sales of manufactured sterile injectable pharmaceuticals to healthcare providers, hospitals, and wholesalers through PhebWeb online ordering system and field sales representatives. Products sold include over 60 medicines across therapeutic areas.
2. License and Distribution Agreements: License and distribution agreements with international partners such as Flexipharm Austrading for UK market access. Phebra out-licenses products globally across Pacific region, Asia, Europe, Canada, South Americas and Middle East.
3. Contract Manufacturing: Contract development and manufacturing services for other pharmaceutical companies on a fee-for-service basis

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels3 records

Core offering

Phebra develops, manufactures, and supplies high-quality sterile injectable pharmaceuticals and critical medicines for serious and life-threatening conditions. Operating from a TGA-licensed, GMP-compliant and FDA-accredited facility in Lane Cove West, Sydney, it produces over 60 medicines across therapeutic categories including antidotes, cardiovascular, oncology, pain management, anaesthesia, neonatal care, and diagnostics, and is licensed to manufacture therapeutic goods for clinical trials. The company also provides contract development and manufacturing services and licenses its products globally through distribution partners.

Product overview

Phebra is an Australian pharmaceutical company that develops, manufactures, and supplies high-quality sterile injectable pharmaceuticals and critical medicines. The core product portfolio includes over 60 medicines across therapeutic areas: antidotes (Acetadote, DigiFab), cardiovascular drugs (Rapiblyk, Brevibloc, Narcan), oncology products (Phenasen/Arsenic Trioxide), pain management (Caldolor, Laceraine Gel, Morphine Oral Solution), emergency medicines, diagnostic agents (Charcotrace, Retinofluor), and infusion solutions. The company operates the PhebWeb online ordering system for customer direct ordering. In March 2024, Phebra established subsidiary Phero Pharma to address medicines shortages through alternative sourcing and in-licensing. Manufacturing is conducted at TGA-licensed facilities in Sydney, with distribution across Australia, New Zealand, Canada, UK, and Singapore.

Differentiator

Problem solved

Functional benefit

Brands

• Phero Pharma: Subsidiary company established to help fulfill medicine shortages in the Australian health system via sourcing alternative products in the global market and in-licensing.

Products and services

• Acetadote (Acetylcysteine) Concentrated Injection Concentrated injectable antidote for paracetamol (acetaminophen) overdose used to protect the liver against hepatotoxicity in hospital and emergency settings.
• Phenasen (Arsenic Trioxide) Concentrated Solution for Infusion Concentrated solution for infusion used for the induction of remission and consolidation in patients with acute promyelocytic leukemia (APL), including marketing approval for IV arsenic trioxide in Canada via Phebra Canada Inc.
• Rapiblyk (Landiolol Hydrochloride) Powder for Injection for Infusion Powder for injection for infusion providing rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter, and non-compensatory sinus tachycardia, supplied to Australian healthcare settings.
• Narcan (Naloxone Hydrochloride) Injection Injectable opioid antagonist used for complete or partial reversal of opioid depression, including respiratory depression, in emergency and hospital settings.
• DigiFab (Digoxin-Specific Antibody Fragment) Powder for Injection Powder for injection used for the treatment of life-threatening or potentially life-threatening digoxin toxicity or overdose in hospital settings.
• Brevibloc (Esmolol Hydrochloride) Injection/Powder Short-acting beta-blocker injection/powder for rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in hospital and perioperative settings.
• Caldolor (Ibuprofen) Concentrated Solution for Injection Concentrated IV solution of ibuprofen for the management of acute postoperative pain and reduction of fever in adults requiring IV administration.
• Laceraine Topical Wound Anaesthetic Gel Topical lidocaine/adrenaline/tetracaine wound anaesthetic gel for wound closure and cleaning of painful minor wounds, supplied to healthcare professionals and hospital settings.
• Tadim (Colistimethate Sodium) Powder for Nebuliser Solution Powder for nebuliser solution indicated for treatment of lung colonisation and infections caused by Pseudomonas aeruginosa in cystic fibrosis patients.
• Cafnea (Caffeine Citrate) Injection/Oral Solution Caffeine citrate injection and oral solution for the short-term treatment of apnoea of prematurity in infants in neonatal hospital settings.
• Syntometrine (Ergometrine and Oxytocin) Injection Injection indicated for active management of the third stage of labour and the prevention and treatment of post-partum haemorrhage.
• Sterile Theatre Packs Ready-to-use sterile theatre packs, including bupivacaine and lidocaine with adrenaline presentations, supplied for surgical anaesthesia and analgesia in hospital operating theatre settings.
• Morphine Oral Solution Oral morphine solution for short-term management of severe pain when other treatment options have failed.
• Aramine (Metaraminol) Solution for Injection Solution for injection for prevention and treatment of acute hypotensive states occurring with spinal anaesthesia, and as adjunctive treatment of hypotension.
• Charcotrace (Activated Charcoal) Injection Activated charcoal injection used as a diagnostic agent for stereotactic localisation of impalpable breast lesions prior to surgical excision.
• Carbosorb X (Activated Charcoal) Suspension Oral activated charcoal suspension indicated for treatment of poisoning and drug overdosage by oral ingestion.
• Ospolot (Sulthiame) Tablets Anticonvulsant tablets indicated for behavioural disorders associated with epilepsy, hyperkinetic behaviour, temporal lobe epilepsy, and myoclonic seizures.

Quantifiable outcome

• 328 tonnes carbon saved per year through energy efficiency initiatives
• +1 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Phero PharmacoreStrategic or Co-development Partner · 1 March 2024New subsidiary pharma company established by Phebra Group to help fulfill medicine shortages in the Australian health system. Core focus is addressing medicines shortages and other pharmaceutical needs via sourcing alternative products in the global market and in-licensing.
• University of WollongongcoreStrategic or Co-development Partner · 1 August 2023Collaborative drug development partnership for leukemias and pancreatic cancer research. Phebra and University of Wollongong working together on promising drug development for treatment of these cancers.
• Flexipharm Austrading Ltd.coreChannel Partner/ Reseller/ Distributor · 3 November 2021UK-based specialty hospital pharma company. Phebra Holdings completed a share purchase agreement with Flexipharm Austrading, strengthening collaboration and expanding Phebra's access to the UK market. Partnership involves a license and distribution agreement with several products already launched in the UK. Phebra has appointed Flexipharm as its exclusive distributor in the United Kingdom.
• MedseniccoreStrategic or Co-development Partner · 1 July 2021Licensing agreement for development of oral arsenic trioxide formulation in the treatment of chronic Graft-Versus-Host and autoimmune diseases. Phebra announced new licensing agreement with Medsenic for this development.
• International Partner for Duchenne Muscular Dystrophy TreatmentminorStrategic or Co-development Partner · 1 May 2020International distribution agreement for manufacture and supply of a new pharmaceutical for treatment of Duchenne Muscular Dystrophy.

Scale indicators7 records

Recent moves16 records

Expansion highlights8 records

Peers

• Biological E:

Broad incumbents

• Aspen Pharmacare: South African-headquartered global specialty pharmaceutical company with significant sterile injectable manufacturing footprint. Comparable because both operate as vertically-integrated specialty injectable manufacturers serving hospital markets across multiple geographies, though Aspen operates at materially larger scale.
• Hikma Pharmaceuticals: Global specialty pharmaceutical company with major sterile injectable franchise serving US, European, and MENA hospital markets. Comparable because both focus on hospital-channel specialty injectable products including critical care medicines, though Hikma operates with significantly larger scale and broader therapeutic coverage.

Direct peers

• Alvogen: Global specialty generics pharmaceutical company with significant injectable portfolio serving hospital and specialty pharmacy channels. Comparable because both focus on specialty injectable products for hospital use across multiple international markets, with overlapping product categories in critical care and antidotes.
• Claris Lifesciences: India-based specialty sterile injectable manufacturer focused on hospital critical care products with global distribution. Comparable because both operate specialty sterile injectable manufacturing businesses targeting hospital critical care customers in regulated international markets, though Claris has broader geographic reach and larger product portfolio.
• Mayne Pharma: Australian specialty pharmaceutical company with branded and generic product portfolio including injectables and specialty therapeutics. Comparable because both are Australian-headquartered specialty pharma companies serving similar hospital and specialty channels, though Mayne has stronger US generic franchise.

Market position

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/phebra

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Phebra